BONG trial of dronabinol for severe breathlessness in severe COPD

Phase 3, randomised, double-blind trial of dronabinol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Sygehus Lillebælt. Primary endpoints: Difference in least-squares mean daily Multidimensional Dyspnea Profile item A1 score between dronabinol and placebo during the 4-week treatment periods and Difference in least-squares mean daily breathlessness interference score between dronabinol and placebo during the 4-week treatment periods. Started Jan 2025; status: completed.